Nordic Life Science
Before Christmas the company announces that the transformation to focus the company’s internal resources on its clinical development projects has now been completed. Redundancies, mainly within research and administration, are
Vinnova, RISE, University of Lund, University of Malmö and 12 companies are investing 110 million SEK during six years on a research center for the development of biopharmaceuticals. “The new
The Danish biotech company has been awarded an investment of 3.6 mEUR from the Novo Holdings REPAIR Impact Fund for development of therapies to combat antimicrobial resistance (AMR). An additional
The patent protects Targovax’ mutant-RAS specific neoantigen peptides, mutant RAS specific T cells and vaccines TG01 and TG02, for the treatment of cancer in combination with chemotherapies. “We are delighted
AstraZeneca’s partner Ironwood Pharmaceuticals has received marketing authorization from the National Medical Products Administration (NMPA) for Linzess (linaclotide) in China for the treatment of adult patients with irritable bowel syndrome with
The Food and Drug Administration (FDA) and the Central Ethics Committee in the United States have accepted Xbranes IND application for initiation of the Xplore trial, a phase III trial
Sponsored Content
Drug & Device development
The company announces that it has completed patient enrollment in its multi-centre, Phase II, randomized, double-blind, placebo-controlled study to explore the efficacy and safety of Sevuparin infusion for the management
The company initiates a phase II-study (proof of concept-study) with the compound Lu AF11167 to confirm its potential as treatment of patients with schizophrenia who are experiencing persistent negative symptoms.
The first patient has been dosed in an investigator-initiated phase II trial of bemcentinib, a selective, potent and orally bio-available AXL inhibitor, in patients with high-risk myelodysplastic syndrome (MDS) who
The Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic kidney disease (CKD) that are either
The company applied today with the Swedish Medical and Pharmaceutical Agency for initiation of a phase I clinical trial of the contrast agent SpagoPix (SN132D) in patients with breast cancer. The
Regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015 is a wholly-owned drug candidate developed for tumor-directed immunotherapy. A
Dr. Johan Luthman has been appointed Executive Vice President and Head of Research & Development in Lundbeck. Luthman will assume his new role and join the Executive Management on 1
Latest news
The company announces that it has completed patient enrollment in its multi-centre, Phase II, randomized, double-blind, placebo-controlled study to explore the efficacy and safety of Sevuparin infusion for the management
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
The company announces that it has completed patient enrollment in its multi-centre, Phase II, randomized, double-blind, placebo-controlled study to explore the efficacy and safety of Sevuparin infusion for the management
The company initiates a phase II-study (proof of concept-study) with the compound Lu AF11167 to confirm its potential as treatment of patients with schizophrenia who are experiencing persistent negative symptoms.
The first patient has been dosed in an investigator-initiated phase II trial of bemcentinib, a selective, potent and orally bio-available AXL inhibitor, in patients with high-risk myelodysplastic syndrome (MDS) who
The Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic kidney disease (CKD) that are either
The company applied today with the Swedish Medical and Pharmaceutical Agency for initiation of a phase I clinical trial of the contrast agent SpagoPix (SN132D) in patients with breast cancer. The
Regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015 is a wholly-owned drug candidate developed for tumor-directed immunotherapy. A
The company has submitted its first national Clinical Trial Application (CTA) to the Food and Drug Administration (FDA) in the US for the start of their Xplore trial for Xlucane. This
All patients in the company’s phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial and no dose limiting toxicities (DLTs) were
Nordic Nanovector announces that updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin (177Lu-lilotomab-satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma (R/R iNHL) have been presented in
The company has presented a comprehensive analysis of monotherapy data from its BGBC003 clinical trial (NCT02488408) with selective AXL inhibitor bemcentinib in patients with relapsed/refractory Acute Myeloid Leukaemia (AML) or
The company is partnering with Beijing University Cancer Hospital and Konica Minolta in a clinical trial to assess the efficacy of scalp cooling for chemotherapy-induced hair loss in women with
LIDDS adds two major university clinics in Lithuania to its ongoing Phase IIb study, the National Cancer Institute in Vilnius and the University Clinic of Kaunas. The two clinics are
The company has announced new data from the CERTiFy (CERAMENT Treatment of Tibia Plateau Fracture defects) study comparing CERAMENT|BVF with autologous iliac bone graft (autograft). “Successfully completing the ground-breaking CERTiFy study, to demonstrate
A1M Pharma announces that the Swedish Medical Products Agency has granted permission to start a clinical Phase I study of ROSgard – a drug candidate developed to prevent Acute Kidney
The company announces that the dosing of patients in its first trial PP-CT01, studying the safety and tolerability of XEN-D0501 in patients with type 2 diabetes, was completed. XEN-D0501 is
The latest research news from the Nordic region
Science Article
Vinnova, RISE, University of Lund, University of Malmö and 12 companies are investing 110 million SEK during six years on a research center for the development of biopharmaceuticals. “The new
After major global successes in the battle against malaria, the positive trend stalled around 2015 – apart from in Zanzibar in East Africa, where only a fraction of the disease
Using DNA origami – DNA-based design of precise nanostructures – scientists at Karolinska Institutet in Sweden and at University of Oslo, Norway, have been able to demonstrate the most accurate
New results could help select patients who might benefit most from BAFF inhibitors for autoimmune diseases. Many autoimmune conditions such as multiple sclerosis and rheumatoid arthritis are more common in
Researchers at Karolinska Institutet present a new method for analyzing how instructions in the genome control how our genes are activated in individual cells. The results give new insights into
Scientists at the Technical University of Denmark upend conventional wisdom about introducing new genes into bacteria. Why do some foreign genes work well in a new host and some do